|
CN106727532A
|
|
The benzimidazolyl and bischloroethylamines radical derivative composition of Psiguadial A are used to prevent and treat kidney fibrosis
|
|
CN106727530A
|
|
The benzimidazolyl and bischloroethylamines radical derivative composition of Psiguadial A are used for anti anoxia
|
|
CN106727531A
|
|
The benzimidazolyl and bischloroethylamines radical derivative composition of Psiguadial A are used for anti-hepatic fibrosis
|
|
CN106727527A
|
|
The imidazole radicals of Psiguadial A and two hydroxyethylamine derivative compositions are used to prevent and treat kidney fibrosis
|
|
CN106727526A
|
|
The imidazole radicals of Psiguadial A and two hydroxyethylamine derivative compositions are used for anti-hepatic fibrosis
|
|
CN106727525A
|
|
The imidazole radicals of Psiguadial A and two hydroxyethylamine derivative compositions are used for anti anoxia
|
|
CN106727569A
|
|
The piperazinyl and 1H tetrazole radical derivatives composition of Psiguadial A are used for anti-acute renal failure
|
|
CN106727568A
|
|
The piperazinyl and 1H tetrazole radical derivatives composition of Psiguadial A are used to prevent and treat hepar damnification
|
|
CN106727572A
|
|
The piperazinyl and 1H tetrazole radical derivatives composition of Psiguadial A are used for anti anoxia
|
|
CN106727573A
|
|
The piperazinyl and 1H tetrazole radical derivatives composition of Psiguadial A are used for increasing leukocyte
|
|
CN106727571A
|
|
The piperazinyl and 1H tetrazole radical derivatives composition of Psiguadial A are used for anti-hepatic fibrosis
|
|
CN106727570A
|
|
The piperazinyl and 1H tetrazole radical derivatives composition of Psiguadial A are used to prevent and treat kidney fibrosis
|
